Protein degradation technology: a strategic paradigm shift in drug discovery

Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due to a lack of active sites, leading to a significant challenge in the design and development...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Haobin, Dong, Jinyun, Cai, Maohua, Xu, Zhiyuan, Cheng, Xiang-Dong, Qin, Jiang-Jiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419833/
https://www.ncbi.nlm.nih.gov/pubmed/34488823
http://dx.doi.org/10.1186/s13045-021-01146-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8419833/
https://www.ncbi.nlm.nih.gov/pubmed/34488823
http://dx.doi.org/10.1186/s13045-021-01146-7

Ejemplares similares